Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "circular-RNA"

3 News Found

WACKER launches contract research services to accelerate next-gen RNA & DNA therapies
R&D | May 23, 2026

WACKER launches contract research services to accelerate next-gen RNA & DNA therapies

The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich

Lilly to acquire Orna Therapeutics in deal valued at up to $2.4 billion
News | February 10, 2026

Lilly to acquire Orna Therapeutics in deal valued at up to $2.4 billion

The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles

Merck and Orna Therapeutics collaborate to advance Orna’s nextgen RNA technology
Biotech | August 17, 2022

Merck and Orna Therapeutics collaborate to advance Orna’s nextgen RNA technology

Collaboration supports multiple discovery efforts, including vaccines

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Global clinical trials are shifting east. Is India ready to lead?

Merck names Miguel Alcalde to lead global commercial strategy; Monia Vial to head North America

Merck wins EU nod for KEYTRUDA-Padcev regimen in muscle-invasive bladder cancer

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Peptides are next frontline therapeutics led by GLP-1: Dr. Vandana Singh, Head - API Regulatory Sciences, Biocon Limited
Peptides are next frontline therapeutics led by GLP-1: Dr. Vandana Singh, Head - API Regulatory Sciences, Biocon Limited
Rising pharma demand driving our India market strategy: Sanjeev Kumar Khandelwal, Head of Division, Characterization Division, Anton Paar India
Rising pharma demand driving our India market strategy: Sanjeev Kumar Khandelwal, Head of Division, Characterization Division, Anton Paar India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International

Packaging